Reducing this risk is a key part of our commitment to driving change for this community, as we work to increase manufacturing capacity to responsibly supply this important medicine. The FDA decision is based on the results of the landmark SELECT phase 3 cardiovascular outcomes trial that examined the effect of adding Wegovy 2.4mg or placebo to cardiovascular standard of care in adults with overweight and obesity with established cardiovascular disease and without diabetes
Demand for GLP-1s, including Novo Nordisk's weight loss treatment Wegovy and diabetes injection Ozempic, has outstripped supply over the last year in the U.S
Without MDWatch Medical Group, I truly dont think Id be alive today Use the arrows to see more real patient stories 4,500+ patients and counting have changed their lives with MDWatch Check your Medicare benefits See if you qualify in minutes free, with no obligation
Semaglutide can lose 10, 20, even 30 percent of its potency without showing any visible change
Both semaglutide and tirzepatide may be considered for non-diabetic patients when clinically appropriate
